- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06704906
Voksen pasientutfall etter ryggradskirurgi med fibergraft BG Putty/Viper Prime
Vurder kliniske og radiografiske resultater av VIPER PRIME/Expedium Spine System og Fibergraft BG Kitty
The Viper Prime/Expedium spine systems are intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion in the treatment of acute and chronic instabilities or deformities of the thoracolumbar and sacral spine. The Fibergraft Bioactive Glass (BG) is engineered to mimic the body's natural bone healing process. While previous studies have compared the use of Viper prime/Expedium spine system in minimally invasive and open surgeries, these studies did not specifically study the clinical and radiographic outcomes of patients who have received these implants in addition to Fibergraft. We aim to recruit patients with degenerative disc disease, spondylolisthesis, trauma, and/or pseudarthrosis who require spine surgery under standard of care and use these implants. We will then follow these patients for a duration of two years to report their clinical and radiographic outcomes to determine fusion, complication rate, and revision surgeries if any.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forente stater, 15213
- University of Pittsburgh Medical Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Adult patients with spinal conditions mentioned in inclusion/exclusion criteria
Beskrivelse
Inclusion Criteria:
- Age ≥ 18 years
- Have a radiograph-based diagnosis of degenerative disc disease, spondylolisthesis, spinal trauma (i.e., fracture or dislocation), spinal stenosis, or deformity (i.e., scoliosis, kyphosis, and/or lordosis), spinal tumor, or pseudoarthrosis/failed fusion.
- Pathology of the thoracolumbar or sacral spine.
- Patients requiring fusion of 1-3 levels
- Patients receiving the surgery/devices as standard of care prescribed by the treating physician.
Exclusion Criteria:
- Patients < 18 years
- Patients with a cervical spine pathology
- Patients with spinal tumors
- Patients with bone density (DEXA) scores < 2.0 will be excluded.
- Current smokers and patients who quit smoking within 6 weeks prior to presentation will be excluded.
- Patients with a BMI > 40kg/m2
- Patients requiring fusion for more than 3 levels will be excluded
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: CASE_ONLY
- Tidsperspektiver: PROSPECTIVE
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Fusion
Tidsramme: 2 years (At baseline, postoperatively at 6 weeks, 3 months, 6 months, 12 months, and 24 months)
|
We will assess fusion with regular x-rays and CT scans at 1 and 2-year postoperatively. |
2 years (At baseline, postoperatively at 6 weeks, 3 months, 6 months, 12 months, and 24 months)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Visual Analog Scale (VAS)
Tidsramme: 2 years (At baseline, postoperatively at 6 weeks, 3 months, 6 months, 12 months, and 24 months)
|
We will have patients fill out validated tools for PROs to assess how the patient is doing postoperatively |
2 years (At baseline, postoperatively at 6 weeks, 3 months, 6 months, 12 months, and 24 months)
|
|
Oswestry Disability Index (ODI)
Tidsramme: 2 years (At baseline, postoperatively at 6 weeks, 3 months, 6 months, 12 months, and 24 months)
|
We will have patients fill out validated tools for PROs to assess how the patient is doing postoperatively |
2 years (At baseline, postoperatively at 6 weeks, 3 months, 6 months, 12 months, and 24 months)
|
|
Short form survey-12
Tidsramme: 2 years (At baseline, postoperatively at 6 weeks, 3 months, 6 months, 12 months, and 24 months)
|
We will have patients fill out validated tools for PROs to assess how the patient is doing postoperatively |
2 years (At baseline, postoperatively at 6 weeks, 3 months, 6 months, 12 months, and 24 months)
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Nitin Agarwal, MD, University of Pittsburgh
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- STUDY24040006
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .